Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress in understanding of relationship between diabetes and colorectal cancer

( views:7, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 23

DOI:: 10.11569/wcjd.v28.i23.1323

Key Word:: 糖尿病;结直肠癌;相关性;发病机制;降糖药

Abstract：目前国内外多项研究发现糖尿病和结直肠癌发生发展密切相关,糖尿病可被视为结直肠癌发生的独立危险因素,其中的病理生理学机制可能涉及到糖尿病患者高血糖、高胰岛素血症与胰岛素样生长因子轴、慢性炎症与氧化应激、胃肠动力障碍以及免疫监视功能受损等.此外,另有研究表明糖尿病对于结直肠癌患者预后也存在相关性.本文主要针对糖尿病及降糖药物与结直肠癌发生发展的相关性及其病理生理学机制的相关研究进行综述,进而对糖尿病患者进行结直肠癌的早诊早治以及合理规范使用降糖药提供理论基础.

Reference

[1]林鑫,郑艳,崔同建.结直肠癌合并2型糖尿病与淋巴结转移及肝转移的关系[J].2016,(1).
[2]刘霞,向开敏.二甲双胍联合Folfox6治疗结直肠癌合并2型糖尿病的临床疗效分析[J].2013,(5).
[3]李瑞湘,洪涛.细胞自噬与2型糖尿病患者并发肿瘤的关系[J].2016,(3).
[4]滕家安,秦俭,梁远,等.2型糖尿病与结直肠癌关系的临床研究[J].2010,(3).
[5]方阳,周宏,夏建福,等.胰岛素对2型糖尿病并发结直肠癌肿瘤预后的影响[J].2012,(35).
[6]Susen Becker,Laure Dossus,Rudolf Kaaks.Obesity related hyperinsulinaemia and hyperglycaemia and cancer development[J].2009,115(2).
[7]Siddharth, Singh,Harkirat, Singh,Preet Paul, Singh,etc.Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis.[J].2013,22.
[8]Ma Yanan,Yang Wanshui,Song Mingyang,etc.Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts[J].2018,119(11).
[9]M M J, Zanders,P A J, Vissers,H R, Haak,etc.Colorectal cancer, diabetes and survival: epidemiological insights.[J].2014,40(2).
[10]Harald Lahm,Paul Amstad,Josiane Wyniger,etc.Blockade of the insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF‐II‐mediated autocrine loop[J].1994,58(3).
[11]Pradhan, Richeek,Yin, Hui,Yu, Oriana H. Y.,etc.The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study[J].2020,43(2).
[12]Yu–Xiao Yang,Sean Hennessy,James D. Lewis.Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients[J].2004,127(4).
[13]McKay GA,Smith CJ,Fisher M.Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.[J].2008,62(5).
[14].Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression[J].2000,92(18).
[15]Shelagh I. Dawson.Long‐term risk of malignant neoplasm associated with gestational glucose intolerance[J].2004,100(1).
[16]Fazenbaker, C.,Yao, Y.,Herbst, R.,etc.Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies[J].2017,36(6).
[17]Fuliang, Tian,Zhipeng, Tang,Guoqi, Song,etc.Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients.[J].2012,5(6).
[18]Armando Rojas,Miguel A. Morales.Advanced glycation and endothelial functions: A link towards vascular complications in diabetes[J].2004,76(7).
[19]C Cocca,G Martin,E Rivera,etc.An experimental model of diabetes and cancer in rats[J].1998,34(6).
[20]Samuel Kutin.Constructing Large Set Systems with Given Intersection Sizes Modulo Composite Numbers[J].2002,11(5).
[21]Evelien Dekker,Pieter J Tanis,Jasper L A Vleugels,etc.Colorectal cancer[J].2019,394(10207).
[22]Grassi,G.,Mancia,G.,Scotti,L.,etc.Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis[J].2012,17(6).
[23]Edward H. Lin,Heinz-Josef Lenz,Mansoor N. Saleh,etc.A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer[J].2014,3(4).
[24]Jin TR,Sun J.Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells[J].2008,20(1).
[25]Shen,H.,Zhang,Y.,Ben,Q.,etc.Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies[J].2011,26(11).
[26]Reid, Steven E.,Kay, Emily J.,Neilson, Lisa J.,etc.Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium[J].2017,36(16).
[27]Ottaiano, Alessandro,Nappi, Anna,Tafuto, Salvatore,etc.Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy[J].2016,90(1).
[28]Flanigan SA,Tan AC,Thorburn A,etc.The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.[J].2010,16(22).
[29]Jeon, Justin Y.,Jeong, Duck Hyoun,Park, Min Geun,etc.Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer.[J].2013,8(2).
[30]Pang, Yuanjie,Kartsonaki, Christiana,Guo, Yu,etc.Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: a prospective study of 0.5 million people[J].2018,72(10).
[31]Lee HY,Crawley S,Hokari R,etc.Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway.[J].2010,36(4).
[32]Rehana L. Ahmed,Kathryn H. Schmitz,Kristin E. Anderson,etc.The metabolic syndrome and risk of incident colorectal cancer[J].2006,107(1).
[33]A F, Hofmann,C, Cravetto,G, Molino,etc.Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism.[J].1987,93.
[34]Helena Cucak,Lars Groth Grunnet,Alexander Rosendahl.Accumulation of M1‐like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization[J].2014,95(1).
[35]Helen King,Tamara Aleksic,Paul Haluska,etc.Can we unlock the potential of IGF-1R inhibition in cancer therapy?[J].2014,40(9).
[36]Anne M, Lewis,Sheelu, Varghese,Hui, Xu,etc.Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment.[J].2006,4.
[37]Muhamad Noor Alfarizal,Kamarudin,Md Moklesur Rahman,Sarker,Jin-Rong,Zhou,etc.Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.[J].2019,38(1).
[38]Sagar, Ghosh,Keith, Ashcraft.An IL-6 link between obesity and cancer.[J].2013,5.
[39]Kan H,Song Y,Kip KE,etc.Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes: A meta-analysis.[J].2011,34(10).
[40]T T, Tran,A, Medline,W R, Bruce.Insulin promotion of colon tumors in rats.[J].1996,5(12).
[41]Mills,K.T.,Bellows,C.F.,Hoffman,A.E.,etc.Diabetes mellitus and colorectal cancer prognosis: A meta-analysis[J].2013,56(11).
[42]中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].2021,(4).
[43]Filion, Kristian B.,Azoulay, Laurent,Doll, Margaret K.,etc.Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies[J].2016,39(3).
[44]María del Mar Roca-Rodríguez,Cristina López-Tinoco,Álvaro Fernández-Deudero,etc.Unfavorable cytokine and adhesion molecule profiles during and after pregnancy, in women with gestational diabetes mellitus[J].2017,64(1).
[45]Becerra,C.R.,Salazar,R.,Garcia-Carbonero,R.,etc.Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial[J].2014,73(4).
[46]Meei-Shyuan Lee,Chih-Cheng Hsu,Mark L Wahlqvist,etc.Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals[J].2011,11(1).
[47]But, Anna,De Bruin, Marie L.,Bazelier, Marloes T.,etc.Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study[J].2017,60(9).
[48]Giovannucci E,Pollak M,Leavitt A,etc.A prospective study of plasma C-peptide and colorectal cancer risk in men.[J].2004,96(7).
[49]VanSaun,M.N..Molecular pathways: Adiponectin and leptin signaling in cancer[J].2013,19(8).
[50]Alberto Puccini,Martin D. Berger,Madiha Naseem,etc.Colorectal cancer: epigenetic alterations and their clinical implications[J].2017,1868(2).
[51]Livingstone,C..IGF2 and cancer[J].2013,20(6).
[52]Barrasa,J.I.,Olmo,N.,Lizarbe,M.A.,etc.Bile acids in the colon, from healthy to cytotoxic molecules[J].2013,27(2).
[53]H. Bernstein,C. Bernstein,C.M. Payne,etc.Bile acids as carcinogens in human gastrointestinal cancers[J].2005,589(1).
[54]Chandrawansa K,Fakih MG,Solit DB,etc.Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.[J].2010,28(27).
[55]Strom BL,Ehrlich SF,Peng T,etc.Cohort study of pioglitazone and cancer incidence in patients with diabetes.[J].2011,34(4).
[56]van der Wall E,Visseren FL,van Kruijsdijk RC.Obesity and cancer: the role of dysfunctional adipose tissue.[J].2009,18(10).
[57]P J JENKINS,G M BESSER,P D FAIRCLOUGH.Colorectal neoplasia in acromegaly[J].1999,44(5).
[58]Feng Chi,Rong Wu,Yue-can Zeng,etc.Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis[J].2013,40(5).
[59]Bernstein C,Holubec H,Bhattacharyya AK,etc.Carcinogenicity of deoxycholate, a secondary bile acid.[J].2011,85(8).
[60]Cohen B. D..Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti-Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871[J].2005.
[61]Grimberg A,Cohen P.Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.[J].2000,183(1).
[62]Hong,S.P.,Kim,W.H.,Kim,T.I.,etc.The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus[J].2012,131(3).
[63]Cam H..List ranking on processor arrays[J].2000,55(2).
[64]Takano, Yuji,Shiota, Goshi,Kawasaki, Hironaka.Analysis of Genomic Imprinting of Insulin-Like Growth Factor 2 in Colorectal Cancer.[J].2000,59(3).
[65]Belharazem, Djeda,Magdeburg, Julia,Berton, Ann-Kristin,etc.Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications[J].2016,51(10).
[66]Yang.Liu,Piao-Piao.Jin,Xue-Cheng.Sun,etc.Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis[J].2018,24(2).
[67]石津浩一.FDG-PET3次元関心領域自動設定機能の試用経験：SUV値の誤差要因に関する考察[J].2009,41(8).
[68]Matthias M. Weber,Christian Fottner,Sun Bin Liu,etc.Overexpression of the insulin‐like growth factor I receptor in human colon carcinomas[J].2002,95(10).
[69]Chao W,D'Amore PA.IGF2: epigenetic regulation and role in development and disease.[J].2008,19(2).
[70]Grzegorz Dworacki,Olzhas Urazayev,Yerbol Bekmukhambetov,etc.Thymic emigration patterns in patients with type 2 diabetes treated with metformin[J].2015,146(3).
[71]Patricia, Wong,Mark G, Weiner,Wei-Ting, Hwang,etc.Insulin therapy and colorectal adenomas in patients with diabetes mellitus.[J].2012,21.
[72]Hakansson, Asa,Molin, Goran.Gut Microbiota and Inflammation[J].2011,3(6).
[73]Michael P. Sanderson,Marco H. Hofmann,Pilar Garin-Chesa,etc.The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy[J].2017,16(10).
[74]Hengmi, Cui,Marcia, Cruz-Correa,Francis M, Giardiello,etc.Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.[J].2003,299(5613).
[75]Michelle L, Baglia,Yong, Cui,Tao, Zheng,etc.Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer.[J].2017,(Spec ).
[76]James X, Zhang.Complexity of drug therapy and its implications for quality of diabetes care.[J].2011,2(7).
[77]Bray Freddie,Ferlay Jacques,Soerjomataram Isabelle,etc.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].2018,68(6).
[78]I N, Colmers,S L, Bowker,J A, Johnson.Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.[J].2012,38(6).
[79]Cheol Min,Shin,Nayoung,Kim,Kyungdo,Han,etc.Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.[J].2020,64.
[80]Lei, Wang,Shuang, Cai,Zan, Teng,etc.Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis.[J].2013,8.
[81]Dapito,D.,Mencin,A.,Gwak,G.-Y.,etc.Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4[J].2012,21(4).
[82]Shinan, Yin,Hua, Bai,Danqing, Jing.Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis.[J].2014,9.
[83]Delon Washo-Stultz,Cara L Crowley-Weber,Katerina Dvorakova,etc.Role of mitochondrial complexes I and II, reactive oxygen species and arachidonic acid metabolism in deoxycholate-induced apoptosis[J].2002,177(2).
[84]Guan,J.,Zhang,H.,Wen,Z.,etc.Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells[J].2014,345(1).
[85]S Freier,O Weiss,M Eran,etc.Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon[J].1999,44(5).
[86]Henrich H,Tomas N,Hinz A,etc.Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation.[J].2011,104(2).
[87]Steven M Haffner.Insulin resistance, inflammation, and the prediabetic state[J].2003,92(Supplement 1).
[88].In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer[J].2014,31(1).
[89]R Loberg,J Tabernero,B Y S Chuah,etc.A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.[J].2013,24(7).
[90]Bu,W.-J.,Song,L.,Zhao,D.-Y.,etc.Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: A meta-analysis of observational studies[J].2014,78(2).
[91].Molecular link mechanisms between inflammation and cancer[J].2012,18(26).
[92]Marks AG,Carroll JM,Purnell JQ,etc.Plasma distribution and signaling activities of IGF-II precursors.[J].2011,152(3).
[93]Wei E. K..A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women[J].2005.
[94]Jia, Wei,Xie, Guoxiang,Jia, Weiping.Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J].2018,15(2).